PriceTargets.com logo

Biofrontera - BFRI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 984.34%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.66 As of 04/24/2024 01:00 AM ET
▲ +0.16 (10.67%)

This chart shows the closing price for BFRI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biofrontera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BFRI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BFRI

Analyst Price Target is $18.00
▲ +984.34% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Biofrontera in the last 3 months. The average price target is $18.00, with a high forecast of $18.00 and a low forecast of $18.00. The average price target represents a 984.34% upside from the last price of $1.66.

This chart shows the closing price for BFRI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Biofrontera. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/31/2023BenchmarkReiterated RatingBuy ➝ Buy$18.00Low
3/9/2023BenchmarkReiterated RatingBuy$140.00Low
1/31/2023BenchmarkReiterated RatingBuy$220.00 ➝ $140.00Low
12/15/2021BenchmarkInitiated CoverageBuy$220.00High
11/24/2021Roth CapitalInitiated CoverageBuy$400.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Biofrontera logo
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $1.66
Low: $1.51
High: $1.71

50 Day Range

MA: $1.37
Low: $0.69
High: $2.38

52 Week Range

Now: $1.66
Low: $0.61
High: $13.42

Volume

62,560 shs

Average Volume

646,464 shs

Market Capitalization

$8.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Biofrontera?

The following Wall Street sell-side analysts have issued reports on Biofrontera in the last twelve months: Benchmark Co..
View the latest analyst ratings for BFRI.

What is the current price target for Biofrontera?

1 Wall Street analysts have set twelve-month price targets for Biofrontera in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 984.3%. Benchmark Co. has the highest price target set, predicting BFRI will reach $18.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $18.00 for Biofrontera in the next year.
View the latest price targets for BFRI.

What is the current consensus analyst rating for Biofrontera?

Biofrontera currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BFRI will outperform the market and that investors should add to their positions of Biofrontera.
View the latest ratings for BFRI.

What other companies compete with Biofrontera?

Other companies that are similar to Biofrontera include TFF Pharmaceuticals, ASLAN Pharmaceuticals, Bionomics, Lixte Biotechnology and Chemomab Therapeutics. Learn More about companies similar to Biofrontera.

How do I contact Biofrontera's investor relations team?

The company's listed phone number is 781-245-1325 and its investor relations email address is [email protected]. The official website for Biofrontera is www.biofrontera-us.com. Learn More about contacing Biofrontera investor relations.